156 related articles for article (PubMed ID: 35978277)
1. Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review.
Cheng K; Liu X; Chen Y; Zhou K; Li Z
BMC Gastroenterol; 2022 Aug; 22(1):388. PubMed ID: 35978277
[TBL] [Abstract][Full Text] [Related]
2. Use of anlotinib in intra-abdominal desmoplastic small round cell tumors: a case report and literature review.
Chen HM; Feng G
Onco Targets Ther; 2019; 12():57-61. PubMed ID: 30588030
[TBL] [Abstract][Full Text] [Related]
3. Effective Treatment of Anlotinib Combined With Chemotherapy in Children With Desmoplastic Small Round Cell Tumor: A Case Series in a Single-center and Literature Review.
Jing XY; Shen CQ; He GQ; Xu RR; Gao J; Guo X
J Pediatr Hematol Oncol; 2024 Apr; 46(3):159-164. PubMed ID: 38408140
[TBL] [Abstract][Full Text] [Related]
4. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
Liu J; Deng YT; Jiang Y
Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review.
Shi C; Feng Y; Zhang LC; Ding DY; Yan MY; Pan L
BMC Cancer; 2018 Mar; 18(1):338. PubMed ID: 29587657
[TBL] [Abstract][Full Text] [Related]
6. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.
Zhang A; Liu B; Xu D; Sun Y
Medicine (Baltimore); 2019 Dec; 98(52):e18435. PubMed ID: 31876723
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
Cui Q; Hu Y; Ma D; Liu H
Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
[TBL] [Abstract][Full Text] [Related]
9. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review.
Zuo R; Zhang C; Lin L; Meng Z; Wang Y; Su Y; Abudurazik M; Du Y; Chen P
Thorac Cancer; 2020 Nov; 11(11):3383-3387. PubMed ID: 32997432
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.
Huang M; Liu Y; Yu M; Li Y; Zhang Y; Zhu J; Li L; Lu Y
Invest New Drugs; 2022 Apr; 40(2):308-313. PubMed ID: 34724131
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
12. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
Sun L; Yang M; Zhang X; Li H; Wu L; Zhang Y; Cai S
Medicine (Baltimore); 2020 May; 99(20):e20053. PubMed ID: 32443311
[TBL] [Abstract][Full Text] [Related]
15. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
Sun C; Ma X; Jiang L; Zhu X
Anticancer Drugs; 2024 Apr; 35(4):358-361. PubMed ID: 38385998
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of advanced ovarian cancer with anlotinib: a case report.
Zhang P; Ma L; Wang X; Zhang R; Dong Y
J Int Med Res; 2020 Dec; 48(12):300060520976824. PubMed ID: 33284728
[TBL] [Abstract][Full Text] [Related]
17. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
[No Abstract] [Full Text] [Related]
18. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
